MEDX Oncology West


Session 10: Targeted Therapy in Skin Malignancies: BRAF and Hedgehog Inhibition

Saturday, November 18     1:45pm – 3:05pm

Description

Patients may not always be offered the most appropriate single and combination targeted therapies that have been proven effective in clinical trials. Currently available clinical data have practice-changing implications for medical oncologists, dermatologists, and related specialists treating skin malignancies. To stay abreast of the latest data, evidence will be presented related to the role of BRAF inhibition and hedgehog signaling in the pathogenesis of basal cell carcinoma (BCC). During this session, BRAF and hedgehog inhibition will be integrated into treatment planning for patients who had progressive disease after surgical, radiation, and/or topical therapies. Participants will have the opportunity to consider the potential benefits and side effects, in order to ensure patients reach or maintain their treatment and quality-of-life goals.

Session Outline

Faculty will discuss 2-3 patient stories to highlight the factors that impact treatment decisions in skin malignancies. The presentation will be interactive featuring the use of iPads throughout the session. The following areas will be discussed:

  • Screening and testing recommendations
  • Safety and efficacy of agents for BRAF-mutated melanoma
  • Current clinical evidence for the use of hedgehog inhibitors in BCC
  • Mechanisms of resistance
  • Role of combination therapy in delaying disease progression
  • Collaboration within the multidisciplinary cancer care team

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 1.25 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.25 hours (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon